RDRobert D. Dayton

Robert D. Dayton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert D. Dayton has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A comparison of viral prevalence versus population coverage as drivers of public health information derived from wastewater sampling

    by William M. Baldwin, Robert D. Dayton, Andrew D. Yurochko, Mohammad A.N. Bhuiyan, Aaron W. Bivins, John A. Vanchiere, Terry Davis, Rona S. Scott, Connie L. Arnold, Christopher G. Kevil, et al.

  • Open Access

    Cre‐dependent AAV vectors for highly targeted expression of disease‐related proteins and neurodegeneration in the substantia nigra

    by Mychal S. Grames, Robert D. Dayton, Kasey L. Jackson, Adam D. Richard, Xiaohong Lu, Ronald L. Klein

    Recombinant adeno‐associated virus (AAV) vectors are a popular genetic approach in neuroscience because they confer such efficient transgene expression in the brain and spinal cord. A number of studies have used AAV to express pathological disease‐related proteins in the dopaminergic neurons of the substantia nigra in situ (e.g ., a‐synuclein to model aspects of Parkinson's disease). The neuropathology and neurodegeneration of Parkinson's disease occur in a circumscribed pattern in the brain, and one of the most important goals of any gene transfer study is accurate, pinpoint targeting. By combining Cre recombinase‐dependent AAVs in Cre‐driver rats in which Cre is expressed only in the tyrosine hydroxylase neurons, we have achieved more highly targeted expression of several disease‐relevant neuropathological proteins in the substantia nigra pars compacta than using constitutive expression AAV vectors. Alpha‐synuclein, tau, transactive response DNA‐binding protein of 43 kDa, or the control fluorescent protein yellow fluorescent protein was individually expressed to induce highly targeted, dopaminergic neuron‐specific neurodegeneration models. The refined targeting foreshadows a next‐generation disease modeling system for expressing neurodegenerative disease‐related proteins in a disease‐relevant manner. We foresee specific utilities of this in vivo AAV vector targeting of pathological proteins to a well‐defined and well‐demarcated cell population.—Grames, M. S., Dayton, R. D., Jackson, K. L., Richard, A. D., Lu, X., Klein, R. L. Cre‐dependent AAV vectors for highly targeted expression of disease‐related proteins and neurodegeneration in the substantia nigra. FASEB J . 32, 4420‐4427 (2018). www.fasebj.org


  • Open Access

    Recombinant AAV9-TLK1B Administration Ameliorates Fractionated Radiation-Induced Xerostomia

    by Prakash Srinivasan Timiri Shanmugam, Robert D. Dayton, Senthilnathan Palaniyandi, Fleurette Abreo, Gloria Caldito, Ronald L. Klein, Gulshan Sunavala-Dossabhoy

    Salivary glands are highly susceptible to radiation, and patients with head and neck cancer treated with radiotherapy invariably suffer from its distressing side effect, salivary hypofunction. The reduction in saliva disrupts oral functions, and significantly impairs oral health. Previously, we demonstrated that adenoviral-mediated expression of Tousled-like kinase 1B (TLK1B) in rat submandibular glands preserves salivary function after single-dose ionizing radiation. To achieve long-term transgene expression for protection of salivary gland function against fractionated radiation, this study examines the usefulness of recombinant adeno-associated viral vector for TLK1B delivery. Lactated Ringers or AAV2/9 with either TLK1B or GFP expression cassette were retroductally delivered to rat submandibular salivary glands (1011 vg/gland), and animals were exposed, or not, to 20 Gy in eight fractions of 2.5 Gy/day. AAV2/9 transduced predominantly the ductal cells, including the convoluted granular tubules of the submandibular glands. Transgene expression after virus delivery could be detected within 5 weeks, and stable gene expression was observed till the end of study. Pilocarpine-stimulated saliva output measured at 8 weeks after completion of radiation demonstrated >10-fold reduction in salivary flow in saline- and AAV2/9-GFP-treated animals compared with the respective nonirradiated groups (90.8% and 92.5% reduction in salivary flow, respectively). Importantly, there was no decrease in stimulated salivary output after irradiation in animals that were pretreated with AAV2/9-TLK1B (121.5% increase in salivary flow; p<0.01). Salivary gland histology was better preserved after irradiation in TLK1B-treated group, though not significantly, compared with control groups. Single preemptive delivery of AAV2/9-TLK1B averts salivary dysfunction resulting from fractionated radiation. Although AAV2/9 transduces mostly the ductal cells of the gland, their protection against radiation assists in preserving submandibular gland function. AAV2/9-TLK1B treatment could prove beneficial in attenuating xerostomia in patients with head and neck cancer undergoing radiotherapy.